Raj Metro Life Sciences Private Limited
Founded in 2010 and headquartered in Maharashtra, India.
2010 | Mumbai, Maharashtra (India) | Active
Raj Metro Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -144.07%
- Ebitda -169.72%
- Net Worth -45.33%
- Total Assets -0.12%
About Raj Metro Life Sciences
Raj Metro Life Sciences Private Limited (RMLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 January 2010 and has a history of 15 years and one month. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Solanki, Nareshkumar Solanki, and Kaluram Vishnoi serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74990MH2010PTC198284
- Company No.
198284
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jan 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Raj Metro Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nareshkumar Solanki  | Director | 01-Jan-2010 | Current |
| Rajendra Solanki | Director | 01-Jan-2010 | Current |
| Kaluram Vishnoi | Additional Director | 16-Aug-2022 | Current |
Financial Performance of Raj Metro Life Sciences.
Raj Metro Life Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 144.07% decrease in profit. The company's net worth observed a substantial decline by a decrease of 45.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raj Metro Life Sciences?
In 2020, Raj Metro Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raj Metro Life Sciences?
Unlock and access historical data on people associated with Raj Metro Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raj Metro Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raj Metro Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
